Avalo Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Wayne, PA
AVTX chart
What traders are saying about $AVTX
Latest postsAvalo Therapeutics, Inc. news
- Exclusive BAC Article: Avalo Therapeutics; Positive Ph2 LOTUS Data Abdakibart HS, Phase 3 Start 1st Half 2027, IND Filing Next-Generation Long-Acting Anti-IL-1β Candidate Same Time, And Catalysts (NASDAQ:AVTX)
Seeking Alpha ·
- Oppenheimer cuts Avalo Therapeutics price target on trial concerns
Investing.com ·
- AVTX Stock Slides As Avalo Faces Wave Of Analyst Downgrades
Timothy Sykes ·
- Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 (NASDAQ:AVTX)
Seeking Alpha ·
- Avalo Therapeutics' positive Phase 2 results su...
Pluang ·
- Avalo Therapeutics Drops To US$6.93, Yet Insiders May Have Sold Too Early
Moomoo ·
- We're Not Very Worried About Avalo Therapeutics' (NASDAQ:AVTX) Cash Burn Rate
Simply Wall Street ·
- Avalo Therapeutics, Inc. Estimates – NASDAQ:AVTX
TradingView ·
- Avalo Therapeutics Inc. (AVTX) Stock Price | Live Quotes & Charts | NASDAQ
Timothy Sykes ·
- Sector Update: Healthcare Stocks Fall Late Afternoon
Yahoo Finance ·
- Avalo Therapeutics Shares Fall After HC Wainwright Downgrade
Yahoo Finance ·
- Avalo Therapeutics price target lowered to $10 from $58 at BTIG
TipRanks ·
Avalo Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M |
| Diluted EPS | $-5.84 | $-20.91 | $-113.58 | $-1063.00 |
| Total assets (year end) | $116.5M | $150.7M | $21.0M | $33.4M |
| Cash and equivalents (year end) | $15.9M | $134.5M | $7.4M | $13.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Avalo Therapeutics, Inc.
- Ticker
- AVTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wayne, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1534120
- Former names
- Cerecor Inc.
Frequently asked questions
What exchange is Avalo Therapeutics, Inc. listed on?
Avalo Therapeutics, Inc. trades on the Nasdaq under the ticker symbol AVTX.
What industry is Avalo Therapeutics, Inc. in?
Avalo Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc.'s business address on file with the SEC is in Wayne, PA.
When does Avalo Therapeutics, Inc.'s fiscal year end?
Avalo Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Avalo Therapeutics, Inc. report?
Avalo Therapeutics, Inc. reported $59,000 in revenue for calendar year 2025, according to its SEC filings.